Abstract
After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
Keywords: Remdesivir, favipiravir, COVID-19, heart, cardiovascular, side effect.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
Volume: 21 Issue: 2
Author(s): Mohammad Amin Shahrbaf, Mohammadreza Tabary and Isa Khaheshi*
Affiliation:
- Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Remdesivir, favipiravir, COVID-19, heart, cardiovascular, side effect.
Abstract: After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
Export Options
About this article
Cite this article as:
Shahrbaf Amin Mohammad, Tabary Mohammadreza and Khaheshi Isa*, Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1871529X21666210812103535
DOI https://dx.doi.org/10.2174/1871529X21666210812103535 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Metabolomics Approach Reveals Altered Plasma Amino Acid and Sphingolipid Profiles Associated with Patholological State in Transition Dairy Cows
Current Metabolomics Cervical Cancer: Are There Potential New Targets? An Update on Preclinical and Clinical Results
Current Drug Targets Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Identification and Detection of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design Epigenetics and the Environmental Regulation of the Brain's Genome and its Function
Current Psychiatry Reviews Editorial [Hot Topic: Chelating Agents in Different Human Diseases (Guest Editor: Valeria Marina Nurchi)]
Current Medicinal Chemistry Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Rat Ultrasonic Vocalizations and Behavioral Neuropharmacology: From the Screening of Drugs to the Study of Disease
Current Neuropharmacology Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology